Ken Herrmann

SPECT/CT

Andreas K. Buck, Stephan G. Nekolla, Sibylle Ziegler et al. · Journal of Nuclear Medicine · 2008 · 279 citations · Full text

Medicine, Nuclear Medicine, Radiology +17

177Lu-PSMA-617 versus a change of androgen receptor pathway inhibitor therapy for taxane-naive patients with progressive metastatic castration-resistant prostate cancer (PSMAfore): a phase 3, randomised, controlled trial

Michael J. Morris, Daniel Castellano, Ken Herrmann et al. · The Lancet · 2024 · 258 citations · Full text

Medicine, Oncology, Urology +17

Health-related quality of life and pain outcomes with [177Lu]Lu-PSMA-617 plus standard of care versus standard of care in patients with metastatic castration-resistant prostate cancer (VISION): a multicentre, open-label, randomised, phase 3 trial

Karim Fizazi, Ken Herrmann, Bernd J. Krause et al. · The Lancet Oncology · 2023 · 109 citations · Full text

Medicine, Oncology, Pain Management +14

A global evaluation of advanced dosimetry in transarterial radioembolization of hepatocellular carcinoma with Yttrium-90: the TARGET study

Marnix Lam, Étienne Garin, Marco Maccauro et al. · European Journal of Nuclear Medicine and Molecular Imaging · 2022 · 95 citations · Full text

Medicine, Nuclear Medicine, Oncology +17

Unspecific¹⁸F-PSMA-1007 Bone Uptake Evaluated Through PSMA-11 PET, Bone Scanning, and MRI Triple Validation in Patients with Biochemical Recurrence of Prostate Cancer

Robert Seifert, Tuğçe Telli, Marcel Opitz et al. · Journal of Nuclear Medicine · 2022 · 70 citations · Full text

Medicine, Nuclear Medicine, Oncology +17